Philippe Boulangeat is an experienced international and business development executive with 40 years of pharmaceutical experience with a strong focus in ophthalmology and deep knowledge of European markets. Philippe was a co-founder of both Sirion Therapeutics and Point Guard Partners LLC where he served as VP of business development and was instrumental in getting US rights for severeal ophthalmic products.
Prior to moving to the United States, Philippe managed international and business development for 20 years at Chauvin, the leading independent European ophthalmic pharmaceutical company before its acquisition by B&L in 2000. In that position he was actively involved in the set up and development of Chauvin subsidiaries in the man European markets, serving also as President of Chauvin in Switzerland and Belgium. He also participated in numerous licensing agreements (both in and out) and the acquisition of ophthalmic companies in UK and Germany which were key for the development of Chauvin in Europe and export markets
Philippe has a MBA from ESCP Europe in Paris, and is fluent in French, English, and Spanish.